Resistance Analysis Following Sotrovimab Treatment in Participants with COVID-19 During the Phase III COMET-ICE Study

Figures

• 

  Figure 1.. Summary of COMET-ICE participants with SARS-CoV-2 spike gene sequences included in the resistance analyses.

• 

  Figure 2.. Median viral load profiles through day 29 for COMET-ICE participants. Median viral loads are presented for participants in the placebo and sotrovimab arms with (black line: placebo, n = 97; green line: sotrovimab, n = 92) or without (orange line: placebo, n = 261; pink line: sotrovimab, n = 246) the presence of a VOC/VOI or single amino acid substitution of interest (E484K, L452R, N501Y, S477N and S494P). Viral loads less than the limit of quantification (LOQ) (2228 copies/ml) were graphed at 3.27 log10 copies/ml, and viral loads less than the lower limit of detection (LOD) (1493 copies/ml) were graphed at 2.87 log10 copies/ml. Median viral loads for all groups were less than the LOQ at day 15 and less than LOD at days 22 and 29. VOC: Variant of concern; VOI: Variant of interest.

• 

  Figure 3.. Median viral load profiles through day 29 for COMET-ICE participants in the placebo and sotrovimab arms with or without epitope substitutions detected at any visit. Median viral load profiles are presented for participants with any epitope substitution (any, black line: n = 72 participants [15 placebo, 57 sotrovimab]) or without epitope substitutions (None, orange line: n = 624 participants [343 placebo, 281 sotrovimab]), as well as for a subset of participants with substitutions at amino acid positions 337 (green line: n = 17 [4 placebo, 13 sotrovimab) or 340 (pink line: n = 28 [1 placebo, 27 sotrovimab]). Participants with substitutions at positions 337 or 340 may be included in >1 category. Viral loads less than the limit of quantification (2228 copies/ml) were graphed at 3.27 log10 copies/ml, and viral loads less than the lower limit of detection (1493 copies/ml) were graphed at 2.87 log10 copies/ml.